US 11,679,138 B2
Vibrio parahaemolyticus bacteriophage Vib-PAP-7 and use of same for inhibiting vibrio parahaemolyticus bacteria proliferation
Seong Jun Yoon, Seoul (KR); Soo Youn Jun, Seoul (KR); An Sung Kwon, Gyeonggi-do (KR); Hyun Min Song, Seoul (KR); Eun Ji Lee, Gyeonggi-do (KR); and Sang Hyeon Kang, Seoul (KR)
Assigned to Intron Biotechnology, Inc., Gyeonggi-do (KR)
Appl. No. 16/611,877
Filed by Intron Biotechnology, Inc., Gyeonggi-do (KR)
PCT Filed Mar. 8, 2018, PCT No. PCT/KR2018/002734
§ 371(c)(1), (2) Date Nov. 8, 2019,
PCT Pub. No. WO2018/208001, PCT Pub. Date Nov. 15, 2018.
Claims priority of application No. 10-2017-0058068 (KR), filed on May 10, 2017.
Prior Publication US 2021/0138005 A1, May 13, 2021
Int. Cl. A61K 35/76 (2015.01); A61P 31/04 (2006.01); C12N 7/00 (2006.01); A23K 20/195 (2016.01); A23K 50/80 (2016.01)
CPC A61K 35/76 (2013.01) [A23K 20/195 (2016.05); A23K 50/80 (2016.05); A61P 31/04 (2018.01); C12N 7/00 (2013.01); C12N 2795/10121 (2013.01); C12N 2795/10132 (2013.01)] 1 Claim
OG exemplary drawing
 
1. A composition for blocking a Vibrio parahaemolyticus infection, inhibiting the development of diseases caused by a Vibrio parahaemolyticus infection, suppressing diseases caused by Vibrio parahaemolyticus, or alleviating the pathological condition of the diseases caused by Vibrio parahaemolyticus, comprising:
maltodextrin and 1×104 plaque-forming units per gram (pfu/g) to 1×1015 pfu/g of proliferated and purified Myoviridae bacteriophage Vib-PAP-7, which has an ability to specifically kill Vibrio parahaemolyticus and a genome represented by SEQ ID NO: 1, and is deposited in the Korean Collection for Type Cultures (KCTC) under accession number KCTC 13247BP,
wherein the maltodextrin and Myoviridae bacteriophage Vib-PAP-7 are in a dried mixture.